Treatment of Advanced Ovarian Cancer When Surgery Is High-Risk or Optimal Cytoreduction Is Unlikely
Clinical scenario: Suspected or confirmed advanced-stage epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are confirmed poor surgical candidates or in whom optimal cytoreduction is considered unlikely at the outset.
Key clinical consideration
Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) should be considered when a patient has a relatively poor performance status or when the extent of disease makes achieving optimal surgical cytoreduction unlikely. This scenario calls for a distinct sequencing of systemic and surgical management compared to primary debulking surgery.
Treatment approach (partial overview)
Following interval debulking surgery, adjuvant platinum-based chemotherapy continues the treatment course to complete the required number of cycles. Maintenance therapy is subsequently considered in accordance with post-primary maintenance recommendations.
The full regimen — including cycle structure, maintenance options, and the complete decision algorithm — is available in the structured protocol below.
References
- Confirmed poor surgical candidate or low likelihood of optimal cytoreduction
- NACT with interval debulking surgery (IDS) should be considered in patients with advanced-stage ovarian cancer who have a relatively poor performance status or have disease with low likelihood of optimal cytoreduction.
- Continue current therapy (for a total of at least 6 cycles)
- A minimum of 6 cycles of treatment is recommended, including at least 3 cycles of adjuvant therapy after surgery.
View source ↗